Patents Assigned to TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
-
Patent number: 12215090Abstract: Compounds are described with the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and n are defined as anywhere herein, which are useful for the treatment of cancer and other dysproliferative diseases.Type: GrantFiled: February 18, 2019Date of Patent: February 4, 2025Assignees: Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc.Inventors: Yoshiyuki Fukase, Mark Duggan, Hans-Guido Wendel, Kamini Singh
-
Publication number: 20240368269Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to DLL3 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: February 28, 2024Publication date: November 7, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: John T. Poirier, Charles Rudin, Jason Lewis, Abdul Khan, David Andrew, Xinlei Chen, Ivo C. Lorenz, Kathryn M. Tully, Salomon Tendler
-
Publication number: 20240360202Abstract: The presently disclosed subject matter provides antibodies that mimic TCR recognition of HPV-derived epitopes presented by HLA class I molecules, antigen-recognizing receptors that target HPV-derived epitopes presented by HLA class I molecules, and methods of using such antibodies.Type: ApplicationFiled: July 1, 2024Publication date: October 31, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapeutics Discovery Institute, Inc.Inventors: David A. Scheinberg, Tao Dao, Mary Ann Pohl, David Andrew, David Andrew
-
Publication number: 20240262910Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD33 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: February 29, 2024Publication date: August 8, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: Anthony Daniyan, Renier J. BRENTJENS, Ivo C. LORENZ, Abdul KHAN
-
RADIOLIGAND BINDING TO ANTI-DLL3 ANTIBODIES FOR PRETARGETED PET IMAGING AND THERAPEUTIC USES THEREOF
Publication number: 20240216557Abstract: The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.Type: ApplicationFiled: February 28, 2024Publication date: July 4, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapeutics Discovery Institute, Inc.Inventors: John T. POIRIER, Charles Rudin, Jason Lewis, Abdul Khan, David Andrew, Xinlei Chen, Ivo C. Lorenz, Kathryn M. Tully, Salomon Tendler -
Publication number: 20240197879Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD33 and cells comprising such CD33-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD33-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: February 29, 2024Publication date: June 20, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: Anthony Daniyan, Renier J. BRENTJENS, Ivo C. LORENZ, Abdul KHAN
-
Publication number: 20240131070Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: December 11, 2023Publication date: April 25, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
-
Publication number: 20220213211Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: March 11, 2022Publication date: July 7, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Publication number: 20220195064Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
